These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 29924357)

  • 41. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Powerful and Real-Time Quantification of Antifungal Efficacy against Triazole-Resistant and -Susceptible Aspergillus fumigatus Infections in Galleria mellonella by Longitudinal Bioluminescence Imaging.
    Vanhoffelen E; Michiels L; Brock M; Lagrou K; Reséndiz-Sharpe A; Vande Velde G
    Microbiol Spectr; 2023 Aug; 11(4):e0082523. PubMed ID: 37466453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review.
    Singh A; Ahmad N; Varadarajan A; Vikram N; Singh TP; Sharma S; Sharma P
    Int J Biol Macromol; 2021 Sep; 187():988-998. PubMed ID: 34324905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
    Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
    Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mucormycosis: New Developments into a Persistently Devastating Infection.
    Danion F; Aguilar C; Catherinot E; Alanio A; DeWolf S; Lortholary O; Lanternier F
    Semin Respir Crit Care Med; 2015 Oct; 36(5):692-705. PubMed ID: 26398536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes.
    Galgóczy L; Lukács G; Nyilasi I; Papp T; Vágvölgyi C
    Acta Biol Hung; 2010 Sep; 61(3):356-65. PubMed ID: 20724281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disseminated Mucormycosis With Cerebral Involvement Owing to Rhizopus Microsporus in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy.
    Ville S; Talarmin JP; Gaultier-Lintia A; Bouquié R; Sagan C; Le Pape P; Giral M; Morio F
    Exp Clin Transplant; 2016 Feb; 14(1):96-9. PubMed ID: 25275881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary mucormycosis.
    Hamilos G; Samonis G; Kontoyiannis DP
    Semin Respir Crit Care Med; 2011 Dec; 32(6):693-702. PubMed ID: 22167397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
    Rodríguez MM; Pastor FJ; Calvo E; Salas V; Sutton DA; Guarro J
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5022-5. PubMed ID: 19786601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
    Gebremariam T; Alkhazraji S; Gu Y; Najvar LK; Borroto-Esoda K; Patterson TF; Filler SG; Wiederhold NP; Ibrahim AS
    Antimicrob Agents Chemother; 2024 May; 68(5):e0154523. PubMed ID: 38557112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.
    Badali H; Cañete-Gibas C; McCarthy D; Patterson H; Sanders C; David MP; Mele J; Fan H; Wiederhold NP
    J Clin Microbiol; 2021 Aug; 59(9):e0123021. PubMed ID: 34232068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.
    Gebremariam T; Wiederhold NP; Fothergill AW; Garvey EP; Hoekstra WJ; Schotzinger RJ; Patterson TF; Filler SG; Ibrahim AS
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7815-7. PubMed ID: 26369977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
    Lewis RE; Liao G; Wang W; Prince RA; Kontoyiannis DP
    Virulence; 2011; 2(4):348-55. PubMed ID: 21788730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis.
    Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Moradi PW; Sussman-Straus GE; Naing E; Kovanda LL; Finkelman MA; Walsh TJ
    Med Mycol; 2021 Feb; 59(2):189-196. PubMed ID: 33313821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents.
    Chitasombat MN; Kontoyiannis DP
    Curr Opin Infect Dis; 2016 Aug; 29(4):340-5. PubMed ID: 27191199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis.
    Kontoyiannis DP; Azie N; Franks B; Horn DL
    Mycoses; 2014 Apr; 57(4):240-6. PubMed ID: 24147728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.
    Gomes MZ; Lewis RE; Kontoyiannis DP
    Clin Microbiol Rev; 2011 Apr; 24(2):411-45. PubMed ID: 21482731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.
    Sun QN; Najvar LK; Bocanegra R; Loebenberg D; Graybill JR
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2310-2. PubMed ID: 12069997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.
    Ben-Ami R; Lewis RE; Tarrand J; Leventakos K; Kontoyiannis DP
    Antimicrob Agents Chemother; 2010 Jan; 54(1):484-90. PubMed ID: 19858263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.